NLRP1 variant M1184V decreases inflammasome activation in the context of DPP9 inhibition and asthma severity

Affiliations

• 1 Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; Department of Medical Biology, University of Melbourne, Parkville, Australia; the Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, Bonn, Germany.
• 2 Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; Department of Medical Biology, University of Melbourne, Parkville, Australia.
• 3 Department of Medicine, University of California, San Francisco, Calif.
• 4 the Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton, Australia; University of Newcastle, Callaghan, Australia.
• 5 the Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton, Australia; University of Newcastle, Callaghan, Australia; Centre for Inflammation, Centenary Institute, Sydney, Australia; Faculty of Science, University of Technology Sydney, Ultimo, Australia.
• 6 Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Australia.
• 7 Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC.
• 8 Department of Medicine, University of California, San Francisco, Calif; Department of Bioengineering & Therapeutic Sciences, University of California, San Francisco, San Francisco, Calif.
• 9 the Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, Bonn, Germany.
• 10 Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
• 11 Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; Department of Medical Biology, University of Melbourne, Parkville, Australia. Electronic address: masters@wehi.edu.au.